Latest advances in thrombolytic therapy.
Despite recent advances in scientific knowledge and the use of sophisticated medical technology, cardiovascular disease remains the leading cause of death in the United States. Thrombolytic therapy offers an exciting modality in the treatment of thromboembolic diseases, especially myocardial infarction. By lysing coronary thrombi early in the evolution of the infarction process, thrombolytic therapy can be an effective means of limiting infarction size and preserving myocardial function. Intravenous nurses play an essential role in promoting the maximal benefits of thrombolytic agents while ensuring patient safety.
Morton
P G
PG
D016255:Anistreplase / Q000627:therapeutic use; D006801:Humans; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000451:nursing / Q000639:trends*; D013927:Thrombosis / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D016255:Anistreplase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator